Rotkreuzklinikum München

Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019) (2019) Lüftner D, Bauerfeind I, Braun M, Brucker SY, Fasching P, Felberbaum R, Hagemann F, et al. Journal article Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto—GBG 84): A randomised phase III trial (2019) Schneeweiss A, Moebus V, Tesch H, Hanusch C, Denkert C, Luebbe K, Huober J, et al. Journal article Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC) (2018) Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, et al. Conference contribution Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study (2018) Pohl E, Schneeweiss A, Hauke J, Moebus V, Furlanetto J, Denkert C, Fasching P, et al. Conference contribution Comparison of vascular closure devices versus manual compression after femoral artery puncture in women gender-based analysis of a large scale, randomized clinical trial (2018) Gewalt SM, Helde SM, Ibrahim T, Mayer K, Schmidt R, Bott-Fluegel L, Hoppe K, et al. Journal article Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials (2018) von Waldenfels G, Loibl S, Furlanetto J, Machleidt A, Lederer B, Denkert C, Hanusch C, et al. Journal article Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44) (2018) Untch M, Von Minckwitz G, Gerber B, Schem C, Rezai M, Fasching P, Tesch H, et al. Journal article Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy (2018) Denkert C, Von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, et al. Journal article Trends in use and outcome of postoperative radiotherapy following mastectomy: A population-based study (2017) Corradini S, Bauerfeind I, Belka C, Braun M, Combs SE, Eckel R, Harbeck N, et al. Journal article Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) (2017) Kuemmel S, Paepke S, Huober J, Schem C, Untch M, Blohmer JU, Eiermann W, et al. Journal article